1. Thirty-two patients with advanced malignant disease were treated with Mithramycin. 2. One patient had a major regression of his disease and 8 patients had significant minor regressions. 3. The toxic effects of the drug are recorded. 4. Changes in serum isoenzyme levels during treatment and the effect of Mithramycin on calcium metabolism are discussed. 5. It is suggested that more detailed studies of the use of the drug for the treatment of carcinoma of the breast, carcinoma of the rectum, fibrosarcoma, cerebral metastases and hepatic metastases are undertaken. Mithramycin was supplied through Pfizer Ltd., Sandwich, by the John L. Smith Memorial for Cancer Research-Chas. Pfizer & Co. Inc., Maywood, New Jersey, U.S.A., where the compound was produced under contract PH 43/64/50, with collaborative research U.S. National Cancer Institute, U.S. Public Health Service. The author was supported by a grant from the British Empire Cancer Campaign for Research. I am indebted to the consultant and nursing staff of the King’s College Hospital Group, without whose co-operation this study would have been impossible. © 1968, The British Empire Cancer Campaign for Research. All rights reserved.
